New maintenance treatment aims to keep favorable risk AML in remission
NCT ID NCT06379360
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests whether a maintenance therapy using a hypomethylating agent (HMA) can help prevent relapse and improve survival in people with favorable risk acute myeloid leukemia (AML). About 77 participants who are already in remission after initial treatment will receive HMA maintenance. The goal is to see if this approach extends the time without leukemia returning.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ACUTE MYELOID LEUKEMIA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
The First Affiliated Hospital of Soochow University
RECRUITINGSuzhou, Jiangsu, 215006, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a pill keep blood cancer at bay after a stem cell transplant?
- Could muscle loss predict blood cancer outcomes?
- Can a modified enzyme starve Hard-to-Treat blood cancers?
- Can a Low-Dose antifungal shield vulnerable patients from deadly fungal infections?
- Can a gentler chemo prep make stem cell transplants safer for blood cancer patients?
- Talking about the end: could guided conversations reduce futile cancer treatments?